Relacorilant

Unassigned

New Medicines

Metastatic pancreatic cancer

Information

New molecular entity
Corcept Therapeutics
Corcept Therapeutics

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials

Category

Non-steroidal, selective modulator (reduces effect) of the glucocorticoid receptor
Pancreatic cancer is the 11th most common cancer in the UK. It accounts for 3 in 100 of all new cancer cases. There are about 10,000 new pancreatic cancer cases every year, which is 27 new cases per day [2].
Metastatic pancreatic cancer
Oral

Cushing's disease - any cause

Information

Licence extension / variation
Corcept Therapeutics
Corcept Therapeutics

Development and Regulatory status

None
Phase III Clinical Trials
Phase III Clinical Trials

Category

Non-steroidal, selective modulator (reduces effect) of the glucocorticoid receptor
Endogenous hypercortisolism affects around 0.6 in 10,000 people in the EU; corticotropin-dependent causes account for about 80–85% of cases, and of these, 80% are due to pituitary adenomas with the rest due to ectopic corticotropin syndrome.
Cushing's disease - any cause
Oral